Daily RS has protective effect against noncolorectal cancer LS cancers, especially for cancers of the upper gastrointestinal tract
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Aug. 18, 2022 (HealthDay News) -- For patients with Lynch syndrome (LS), daily resistant starch (RS) seems to have a lasting protective effect against noncolorectal cancers, according to a study published online July 25 in Cancer Prevention Research.
John C. Mathers, Ph.D., from Newcastle University in the United Kingdom, and colleagues present long-term cancer outcomes based on a planned 10-year follow-up from recruitment in the CAPP2 trial in which participants with LS were randomly assigned to 30 g RS or placebo daily for up to four years. Overall, 463 and 455 participants received RS and placebo, respectively.
The researchers observed no difference in colorectal cancer incidence at up to 20 years of follow-up (52 and 53 patients diagnosed among those assigned to RS versus placebo), but fewer participants had noncolorectal LS cancers among those assigned to RS versus placebo (27 versus 48; intention-to-treat [ITT] analysis hazard ratio, 0.54). The protective effect on RS against noncolorectal cancer LS cancers was confirmed by calculating incidence rate ratios in an ITT analysis allowing for multiple primary cancer diagnoses among participants (incidence rate ratio, 0.52). For cancers of the upper gastrointestinal (GI) tract, these effects were particularly pronounced (five versus 21 diagnoses with RS and placebo, respectively). The ITT analysis showed no effect of RS on colorectal cancer risk. No interaction was seen between aspirin and RS treatment.
"The effect was most obvious in the upper part of the gut," Mathers said in a statement. "This is important as cancers of the upper GI tract are difficult to diagnose and often are not caught early on."
Several authors disclosed financial ties to the pharmaceutical and nutrition industries.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles